JP2025010296A5 - - Google Patents

Download PDF

Info

Publication number
JP2025010296A5
JP2025010296A5 JP2024190215A JP2024190215A JP2025010296A5 JP 2025010296 A5 JP2025010296 A5 JP 2025010296A5 JP 2024190215 A JP2024190215 A JP 2024190215A JP 2024190215 A JP2024190215 A JP 2024190215A JP 2025010296 A5 JP2025010296 A5 JP 2025010296A5
Authority
JP
Japan
Prior art keywords
cell
protein
hla
classical
class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024190215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025010296A (ja
Filing date
Publication date
Priority claimed from JP2020166783A external-priority patent/JP7260182B2/ja
Application filed filed Critical
Publication of JP2025010296A publication Critical patent/JP2025010296A/ja
Publication of JP2025010296A5 publication Critical patent/JP2025010296A5/ja
Pending legal-status Critical Current

Links

JP2024190215A 2011-04-20 2024-10-30 β２ミクログロブリン欠損細胞 Pending JP2025010296A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161477474P 2011-04-20 2011-04-20
US61/477,474 2011-04-20
JP2020166783A JP7260182B2 (ja) 2011-04-20 2020-10-01 β２ミクログロブリン欠損細胞
JP2023054810A JP7586528B2 (ja) 2011-04-20 2023-03-30 β２ミクログロブリン欠損細胞

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023054810A Division JP7586528B2 (ja) 2011-04-20 2023-03-30 β２ミクログロブリン欠損細胞

Publications (2)

Publication Number Publication Date
JP2025010296A JP2025010296A (ja) 2025-01-20
JP2025010296A5 true JP2025010296A5 (https=) 2025-07-03

Family

ID=46051930

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014506508A Pending JP2014513948A (ja) 2011-04-20 2012-04-18 β２ミクログロブリン欠損細胞
JP2018156070A Pending JP2018174946A (ja) 2011-04-20 2018-08-23 β２ミクログロブリン欠損細胞
JP2020166783A Active JP7260182B2 (ja) 2011-04-20 2020-10-01 β２ミクログロブリン欠損細胞
JP2023054810A Active JP7586528B2 (ja) 2011-04-20 2023-03-30 β２ミクログロブリン欠損細胞
JP2024190215A Pending JP2025010296A (ja) 2011-04-20 2024-10-30 β２ミクログロブリン欠損細胞

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2014506508A Pending JP2014513948A (ja) 2011-04-20 2012-04-18 β２ミクログロブリン欠損細胞
JP2018156070A Pending JP2018174946A (ja) 2011-04-20 2018-08-23 β２ミクログロブリン欠損細胞
JP2020166783A Active JP7260182B2 (ja) 2011-04-20 2020-10-01 β２ミクログロブリン欠損細胞
JP2023054810A Active JP7586528B2 (ja) 2011-04-20 2023-03-30 β２ミクログロブリン欠損細胞

Country Status (6)

Country Link
US (3) US20140134195A1 (https=)
EP (1) EP2699593B2 (https=)
JP (5) JP2014513948A (https=)
CA (2) CA3205636A1 (https=)
DK (1) DK2699593T4 (https=)
WO (1) WO2012145384A1 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145384A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
US20150056225A1 (en) * 2012-04-17 2015-02-26 University Of Washington Through Its Center For Commercialization HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof
CA3177929A1 (en) * 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
BR112015030211A2 (pt) * 2013-06-03 2017-08-22 Theravectys Vetores lentivirais contendo uma sequência promotora a montante da mhc de classe i, mhc de classe ii ou microglobulina beta-2
ES3063961T3 (en) 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
MX373460B (es) 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
WO2016069282A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
WO2016073955A2 (en) 2014-11-06 2016-05-12 President And Fellows Of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
WO2018064594A2 (en) * 2016-09-29 2018-04-05 Nantkwest, Inc. Hla class i-deficient nk-92 cells with decreased immunogenicity
KR20250007053A (ko) * 2017-05-23 2025-01-13 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 타겟화된 치료학적 면역조절을 위한 mhc 클래스 ib 분자와 펩타이드의 조합
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
KR20200075851A (ko) * 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
EP3727467A4 (en) * 2017-12-22 2021-12-01 Centivax, Inc. MAJOR HISTOCOMPATIBILITY COMPLEX (CMH) COMPOSITIONS AND CORRESPONDING PROCEDURES FOR USE
EP3754018A4 (en) 2018-02-16 2021-11-24 Kyoto University LOW ANTIGENIC CELL PRODUCTION PROCESS
CN112534044A (zh) * 2018-02-16 2021-03-19 凯德药业股份有限公司 经修饰的多能干细胞及制备和使用方法
WO2019231266A1 (ko) * 2018-05-30 2019-12-05 주식회사 강스템바이오텍 Hla 유전자가 제거된 인간 유도만능줄기세포 유래 중간엽줄기세포 및 그의 제조 방법
US12331318B2 (en) 2018-07-13 2025-06-17 Lothar Germeroth Non-immunogenic engineered tissue and methods of producing and using the same
EP3843798A1 (en) 2018-08-31 2021-07-07 Wisconsin Alumni Research Foundation Generating arterial endothelial cell-seeded vascular grafts
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
US12497593B2 (en) 2018-09-07 2025-12-16 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
CN113195724A (zh) * 2018-09-26 2021-07-30 新加坡国立大学 低免疫原性的工程化人类间充质基质细胞，制备方法和试剂盒
KR102840400B1 (ko) 2018-12-12 2025-08-04 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
WO2020168122A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
JP7286796B2 (ja) 2019-04-03 2023-06-05 プレシジョン バイオサイエンシズ，インク． マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
TW202115245A (zh) * 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
KR20220058579A (ko) 2019-09-05 2022-05-09 크리스퍼 테라퓨틱스 아게 보편적 공여자 세포
US11104918B2 (en) * 2019-09-05 2021-08-31 Crispr Therapeutics Ag Universal donor cells
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
EP4048802A4 (en) * 2019-10-22 2023-11-22 The Trustees of Columbia University in the City of New York Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice
CN115397993A (zh) * 2020-01-10 2022-11-25 株式会社Lg化学 包含共表达mhc和肿瘤抗原的抗原呈递细胞的组合物和使用所述组合物的癌症疗法
MX2022011245A (es) 2020-03-11 2023-01-11 Bit Bio Ltd Método de generación de células hepáticas.
US20230348854A1 (en) * 2020-05-08 2023-11-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Chimeric antigen receptors (cars) targeting natural killer cells
EP4149525A4 (en) * 2020-05-15 2024-08-28 Rxcell Inc. HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES
WO2021242935A1 (en) * 2020-05-26 2021-12-02 Cue Biopharma, Inc. Antigen presenting polypeptide complexes and methods of use thereof
IL300484A (en) 2020-08-19 2023-04-01 Astellas Pharma Inc A human non-naturally occurring modified IgG FC region that specifically binds to a non-naturally occurring modified FC receptor
EP4200023A4 (en) * 2020-08-23 2024-10-30 Applied StemCell, Inc. Hla-f-modified cells and methods
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022129472A1 (en) 2020-12-18 2022-06-23 Novo Nordisk A/S Safe immuno-stealth cells
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022136215A1 (en) 2020-12-21 2022-06-30 Novo Nordisk A/S Safe immuno-stealth cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
KR20230146007A (ko) 2020-12-31 2023-10-18 크리스퍼 테라퓨틱스 아게 범용 공여자 세포
TW202246494A (zh) * 2021-01-26 2022-12-01 美商艾姆比斯藥品公司 基因改造肝細胞群
TW202302839A (zh) 2021-03-09 2023-01-16 國立研究開發法人理化學研究所 低免疫原性視網膜色素上皮細胞之製造方法
EP4323395A4 (en) * 2021-04-12 2025-04-02 Memorial Sloan Kettering Cancer Center MANIPULATED HLA MOLECULES FOR T CELL AND NK CELL ACTIVATION AND EXPANSION
US20240368541A1 (en) 2021-05-03 2024-11-07 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
WO2022235869A1 (en) 2021-05-07 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature hepatocytes
AU2022299551A1 (en) * 2021-06-23 2024-01-18 Editas Medicine, Inc. Engineered cells for therapy
EP4407028A4 (en) 2021-09-24 2025-08-06 Cira Found METHOD FOR PRODUCING MODIFIED HUMAN INDUCED PLURIPOTENT STEM CELLS
WO2023069480A1 (en) * 2021-10-20 2023-04-27 Vascugen, Inc. Hypoimmune vasculogenic cells
AU2023246279A1 (en) 2022-04-01 2024-11-14 LogoMix, Inc. Cell suitable for gene engineering, cell engineering and cellular medicine, and method for producing same
EP4547825A1 (en) 2022-07-01 2025-05-07 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
IL318429A (en) 2022-08-23 2025-03-01 Astellas Inst For Regenerative Medicine Photoreceptor rescue cell (PRC) compositions and methods for treating eye disorders
WO2024044750A2 (en) * 2022-08-26 2024-02-29 Beam Therapeutics Inc. Modified allogeneic cells and methods and compositions for the preparation thereof
EP4610277A1 (en) 2022-10-25 2025-09-03 Daiichi Sankyo Company, Limited Method for avoiding immune rejection using agonist for inhibitory kir
WO2024107551A1 (en) * 2022-11-17 2024-05-23 The Trustees Of Indiana University Novel biomarker and target for treating pulmonary hypertension
WO2024149906A1 (en) 2023-01-13 2024-07-18 Laverock Therapeutics Limited Cell context-specific gene regulation using inhibitory rnas
WO2025003393A1 (en) 2023-06-30 2025-01-02 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells
WO2025070822A1 (ja) * 2023-09-29 2025-04-03 味の素株式会社 Ｈｌａ遺伝子改変細胞
GB202316281D0 (en) * 2023-10-24 2023-12-06 Replay Holdings Inc Methods and compositions for modulating immune cell activity in cellular therapy
WO2025235955A1 (en) * 2024-05-10 2025-11-13 Bluerock Therapeutics Lp Genetically engineered cells for enhanced immune evasion and methods thereof
WO2026035951A2 (en) 2024-08-07 2026-02-12 Legend Biotech Ireland Limited Cells overexpressing cd43 and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
WO1992009688A1 (en) * 1990-11-21 1992-06-11 Massachusetts Institute Of Technology MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
CA2110946A1 (en) 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
AU6869198A (en) 1997-03-25 1998-10-20 Morphogenesis, Inc. Universal stem cells
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
EP0995798A1 (en) 1998-10-24 2000-04-26 Novimmune Sa Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
DE60142475D1 (de) 2000-03-27 2010-08-12 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20040225112A1 (en) 2003-05-06 2004-11-11 Crew Mark D. Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
FR2856599A1 (fr) * 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
JP2007508018A (ja) * 2003-10-08 2007-04-05 べト−ステム インコーポレイテッド 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
US8105831B2 (en) 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
CA2683060C (en) 2007-04-06 2018-01-16 International Stem Cell Corporation Patient-specific stem cell lines derived from human parthenogenetic blastocysts
JP5267969B2 (ja) * 2007-12-04 2013-08-21 学校法人慶應義塾 癌ワクチン
EP2184297A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G polypeptides and pharmaceutical uses thereof
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
WO2012145384A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
KR102366081B1 (ko) 2012-07-31 2022-02-23 에이지엑스 쎄라퓨틱스, 인크. Hla g-변형된 세포 및 방법

Similar Documents

Publication Publication Date Title
JP2025010296A5 (https=)
JP2024144548A5 (https=)
JP2022162047A5 (https=)
JP7130571B2 (ja) Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
Correa et al. Most gamma delta T cells develop normally in beta 2-microglobulin-deficient mice.
Ennis et al. Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness
Suzuki et al. Asymmetric signaling requirements for thymocyte commitment to the CD4+ versus CD8+ T cell lineages: a new perspective on thymic commitment and selection
Long et al. Stress signals activate natural killer cells
Hunt et al. HLA and maternal‐fetal recognition
JP5829993B2 (ja) Ｈｉｖ感染に対する幹細胞スクリーニングおよび移植治療
JPH06509462A (ja) レセプターキメラ体による細胞性免疫の再設定
Le Bouteiller et al. Is antigen presentation the primary function of HLA-G?
Sun et al. Molecular cloning and characterization of carp (Cyprinus carpio L.) CD8β and CD4-like genes
Wiendl et al. An autoreactive γδ TCR derived from a polymyositis lesion
JP3832856B2 (ja) Ｃｄ４デコイレセプターを有する細胞ならびに関連する分子および方法
CN117886919A (zh) 识别HLA-A2限制性乙肝病毒HBs346-354表位的TCR及其用途
Oyoshi et al. Preferential expansion of Vγ9-JγP/Vδ2-Jδ3 γδ T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection
JP2005519877A5 (ja) Hiv感染に対する幹細胞スクリーニングおよび移植治療
Orchansky et al. Activation-induced cell death in proliferating T cells is associated with altered tyrosine phosphorylation of TCR/CD3 subunits.
IL314832A (en) Hiv-specific binding molecules and tcr
AU2005298245A1 (en) A thymus-specific protein
Zhou et al. Immune suppression via IL-4/IL-10-secreting T cells: a nontoxic property of anti-HIV agent trichosanthin
Tashiro-Yamaji et al. Macrophage MHC receptor 2: a novel receptor on allograft (H-2DdKd)-induced macrophage (H-2DbKb) recognizing an MHC class I molecule, H-2Kd, in mice
JP2002539804A5 (https=)
FR2736931A1 (fr) Sequences regulatrices issues du gene cd4 et a expression specifique dans les lymphocytes t matures